Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7981025 | 0.82 | MAPK1 (0.56) | DDB1CRBNMAPK1ALDH1A1CYP2C19 | |
| SCHEMBL873535 | 0.79 | DDB1 (0.51) | DDB1CRBNMAPK1ALDH1A1CYP2C19 | |
| SCHEMBL4491902 | 0.79 | KMT2A (0.44) | MAPK1ALDH1A1CYP2C19CYP1A2L3MBTL1 | |
| SCHEMBL875841 | 0.79 | MAPK1 (0.58) | MAPK1ALDH1A1CYP2C19CYP1A2L3MBTL1 | |
| SCHEMBL877603 | 0.79 | POLB (0.53) | DDB1CRBNMAPK1ALDH1A1CYP2C19 | |
| SCHEMBL4501819 | 0.79 | KMT2A (0.44) | MAPK1ALDH1A1CYP2C19CYP1A2L3MBTL1 | |
| SCHEMBL31708217 | 0.76 | HSD17B10 (0.44) | MAPK1ALDH1A1CYP2C19CYP1A2L3MBTL1 | |
| SCHEMBL5569137 | 0.75 | KMT2A (0.42) | MAPK1ALDH1A1CYP2C19CYP1A2L3MBTL1 | |
| SCHEMBL14517050 | 0.75 | ALDH1A1 (0.56) | DDB1CRBNMAPK1ALDH1A1CYP2C19 | |
| SCHEMBL19463659 | 0.75 | DDB1 (0.51) | DDB1CRBNALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850234-B2 | Pyridine derivatives as soft rock inhibitors | REDX PHARMA PLC (GB) | 2017-12-26 | — | — | US | disclosed |
| US-9850234-B2 | Pyridine derivatives as soft rock inhibitors | REDX PHARMA PLC (GB) | 2017-12-26 | — | — | US | disclosed |
| US-9850234-B2 | Pyridine derivatives as soft rock inhibitors | REDX PHARMA PLC (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170247357-A1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | REDX PHARMA PLC (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247357-A1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | REDX PHARMA PLC (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247357-A1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | REDX PHARMA PLC (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9682963-B2 | Pyridine derivatives as soft rock inhibitors | REDX PHARMA PLC (GB) | 2017-06-20 | — | — | US | disclosed |
| US-9682963-B2 | Pyridine derivatives as soft rock inhibitors | REDX PHARMA PLC (GB) | 2017-06-20 | — | — | US | disclosed |
| US-9682963-B2 | Pyridine derivatives as soft rock inhibitors | REDX PHARMA PLC (GB) | 2017-06-20 | — | — | US | disclosed |
| EP-2951172-B1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | AMAKEM NV (BE) | 2017-03-29 | — | — | EP | disclosed |
| EP-2951172-B1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | AMAKEM NV (BE) | 2017-03-29 | — | — | EP | disclosed |
| US-20150361072-A1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | AMAKEM NV (BE) | 2015-12-17 | — | — | US | disclosed |
| EP-2951172-A1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | Amakem NV (BE) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014118133-A1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | AMAKEM NV (BE) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014118133-A1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | AMAKEM NV (BE) | 2014-08-07 | — | — | WO | disclosed |
| EP-2619177-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038943-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361072-A1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | ROCK1, ROCK2, ROR1 | DDB1 4496/4885CRBN 3672/4885MAPK1 30/4885 |
| US-20170247357-A1 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS | ROCK1, ROCK2, RHOT2 | DDB1 3675/4885CRBN 2515/4885MAPK1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.